CG Invites Co., Ltd. (KOSDAQ:083790)

South Korea · Delayed Price · Currency is KRW

966.00

+9.00 (0.94%)

Sep 9, 2026, 3:30 PM KST

Market Cap	74.28B -48.8%
Revenue (ttm)	30.11B +185.5%
Net Income	428.90M
EPS	5.58
Shares Out	76.89M
PE Ratio	173.19
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	966.00
Previous Close	957.00
Day's Range	966.00 - 966.00
52-Week Range	711.00 - 1,900.00
Beta	0.06
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About CG Invites

CG Invites Co., Ltd., a biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea. It offers Acelex (polmacoxib), an anti-inflammatory and pain relief drug, as well as CG-650, an anti-inflammatory drug, currently under phase 1 stage for the treatment of osteoarthritis; CG-651, an anti-inflammatory drug, currently under phase 1 stage for the treatment of neuropathic pain; and CG-652, an anti-inflammatory drug, currently under phase 1 stage for the treatment of rheumatoid arthritis. The compan... [Read more]

Industry Medical - Pharmaceuticals

Sector Healthcare

Founded 2000

Employees 71

Stock Exchange KOSDAQ

Ticker Symbol 083790

Full Company Profile

Financial Performance

In 2025, CG Invites's revenue was 27.39 billion, an increase of 277.64% compared to the previous year's 7.25 billion. Losses were -3.52 billion, -93.17% less than in 2024.

Financial Statements